This message was sent to ##Email##
|
|
|
|
|
AST
With the growing concern about the Coronavirus (COVID-19), the AST has published FAQ pages and other resources for both professionals and patients.
READ MORE
AST
The American Society of Transplantation, representing a majority of medical professionals engaged in the field of solid organ transplantation, believes that it is critical under the current circumstances brought forth by COVID-19 pandemic to protect the health and safety of both our patients and our health care providers.
We strongly believe that it is in the best interest of organ donation and transplant team members to limit the recovery of organs to local teams, unless there are extenuating reasons for the transplanting team to perform the recovery. We believe that keeping organ recovery to local surgical teams within the donor hospital will help limit exposure to COVID-19 infection due to travel. We believe this temporary action is a small but critical step in reducing the continued spread of this virus.
AST
Information regarding COVID-19 is changing rapidly. This document will be updated with the evolving issues related to medication access and drug shortages/supply chain issues within the United States of America during the pandemic.
 |
|
Promoted by
Veloxis Pharmaceuticals
Now you can see the different ways that different formulations are released and absorbed in the gastrointestinal system. You’ll also have the opportunity to explore comparative pharmacokinetic results in rapid metabolizers, efficacy data over 2 years, and safety information.
Watch Video
|
|
AST
On March 23, several transplant organizations from around the world partnered to develop this educational webinar for the organ donation and transplantation communities. Our goal is to share experiences to date and respond to your questions about the impact of COVID-19 on organ donation and transplantation. The recording is now available on YouTube.
| AST Membership Renewal Period Extended
|
AST
The AST realizes that membership renewals are not your priority right now. In order to better support our members, we have extended the membership renewal period until May 31. All members still within the grace period will have access to their member benefits through this time to best help you continue to serve the transplant community during the crisis.
Veloxis Pharmaceuticals
 Explore this phase 3 randomized, double-blind, double-dummy, multicenter, multinational, non-inferiority trial published in the American Journal of Transplantation. The study examined treatment failures defined as BPAR, graft failure, death, and delayed graft
function at 3 months and 12 months.
READ MORE
AST
The election for COP Executive Committee members (Co-Chairs, Members-at-Large, and Early Career Members-at-Large) will be open from Wednesday, April 1, through Tuesday, April 14. An email will be sent to members with more information.
READ MORE
AST
The Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2020, also known as the Immuno Bill, was just introduced in the Senate. This legislation would extend Medicare coverage of immunosuppressive drugs for kidney transplant recipients, which is currently limited to just 36 months. Please take a moment to contact your Senators about this important legislation (and if you haven’t already, please also reach out to your House representative to do the same!)
Contact Congress Today
|
|
AST
Transplant professionals have increasing demands on their time. Finding time in one’s day to attend conferences or to read journals is challenging. Transplant in 10 is intended to provide transplant professionals with short, easily accessible videos on key and updated topics in 10 minutes.
READ MORE
| | UPCOMING EDUCATION EVENTS |
AST
April 15, 2020 | 2 pm ET | Online Activity
For more information, click here.
|
TruGraf® - The 1st and only non-invasive test to rule out “silent" subclinical rejection in stable kidney transplant recipients
The only test to be reimbursed as an alternative to surveillance biopsies
Developed by Clinicians for Clinicians
Learn More
|
|
|
|
|
Reach Your Prospects Every Week
Thousands of industry professionals subscribe to association news briefs, which allows your company to push messaging directly to their inboxes and take advantage of the association's brand affinity.
Connect with Highly Defined Buyers and Maximize Your Brand Exposure
|
|
|
|
|
AST
May 4, 2020 | 2 pm ET | Online Activity
For more information, click here.
AST
May 19, 2020 | 2 pm ET | Online Activity
For more information, click here.
|
Promoted by
|
|
|
|
 |
JAMA Cardiology
Increasing numbers of confirmed cases and mortality rates of coronavirus disease 2019 (COVID-19) are occurring in several countries and continents. Information regarding the impact of cardiovascular complication on fatal outcome is scarce.
READ MORE
JAMA
Coronavirus disease 2019 (COVID-19) is a pandemic with no specific therapeutic agents and substantial mortality. It is critical to find new treatments. All five patients (age range, 36-65 years; two women) were receiving mechanical ventilation at the time of treatment and all had received antiviral agents and methylprednisolone.
READ MORE
|
|
American Association for the Study of Liver Disease via Wiley Online Library
Following the outbreak in China, the Lombardy region of Italy has become one of the areas of highest incidence of
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As the outbreak grew to a pandemic, many health centers
worldwide raised the concern that immunocompromised patients may be at high risk of developing a severe
respiratory disease called COVID-19.
READ MORE
The New England Journal of Medicine
Long-term care facilities are high-risk settings for severe outcomes from outbreaks of COVID-19, owing to both the advanced age and frequent chronic underlying health conditions of the residents and the movement of healthcare personnel among facilities in a region.
READ MORE
American Journal of Transplantation via Wiley Online Library
Four independent pretransplantation risk factors were associated with one‐year mortality after transplantation in the training cohort: age ≥53 years (p = 0.044), pre‐LT arterial lactate level ≥4mml/l (p = 0.013), mechanical ventilation with PaO2/FiO2 ≤200mmHg (p = 0.026) and pre‐LT leukocyte count ≤10G/l (p = 0.004). A simplified version of the model was derived by assigning one-point to each risk factor: the transplantation for Aclf‐3 model (TAM) score.
READ MORE
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
